Anthrax immune globulin explained

Tradename:Anthrasil
Routes Of Administration:Intravenous
Legal Ca:Rx-only
Legal Ca Comment:[1]
Legal Us:Rx-only
Unii:VKZ83S945Z
Chemspiderid:none

Anthrax immune globulin, tradename Anthrasil, is a human immune globulin that is used in combination with antibiotics to treat anthrax.[2] It was developed by Cangene and purchased in 2011 by the Biomedical Advanced Research and Development Authority (BARDA) under Project Bioshield. On 24 March 2015 it was granted approval by the United States Food and Drug Administration for use in treating inhalation anthrax in conjunction with antibiotics.[3] [4] __TOC__

Preparation

Anthrax immune globulin is prepared from the plasma of donors who have been vaccinated against anthrax.

Safety and efficacy testing

Due to the ethical and feasibility concerns with testing the efficacy of anthrax immune globulin in humans, it was tested in rabbits and monkeys under the FDA's animal efficacy rule. Following efficacy testing, anthrax immune globulin was tested for safety in human volunteers, where the most common side effects were headache, back pain, nausea and infusion site pain and swelling.

Notes and References

  1. Web site: Extraordinary use . . 9 May 2018 . 13 April 2024.
  2. Savransky V, Ionin B, Reece J . Current Status and Trends in Prophylaxis and Management of Anthrax Disease . Pathogens (Basel, Switzerland) . 9 . 5 . May 2020 . 370 . 32408493 . 7281134 . 10.3390/pathogens9050370 . free .
  3. Web site: FDA approves treatment for inhalation anthrax. 25 March 2015. United States Food and Drug Administration.
  4. Web site: Anthrasil Approval History. 26 March 2015. Drugs.com.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Anthrax immune globulin".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.